FOLH1 and prostate carcinoma: The RNA aptamer A10 is reported to deliver therapeutic CRISPR/Cas9-gRNA targeting polo-like kinase 1, a pro-survival gene overexpressed in most human tumors into prostate cancer cells via specifically binding to the cell-surface receptor PSMA.